13F filer · CIK 924223
BB BIOTECH AG
SCHAFFHAUSEN, V8 · filing since Q2 2013 · last filing Aug 14, 2026
Reported value
$4.0B
+$856.5M vs prior
Positions
35
New / sold out
2 / 1
Added / reduced
14 / 6
Turnover
4.5%
buys $159.0M · sells $159.5M
Top-10 weight
64.7%
Biggest buys vs Q4 2018
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | Crispr Therapeutics AG | +810,462 | – | +$29.0M |
| Added | Audentes Therapeutics, Inc. | +600,200 | +78.0% | +$23.4M |
| Added | Nektar Therapeutics | +639,701 | +46.3% | +$21.5M |
| Added | Myokardia Inc. | +387,647 | +44.2% | +$20.2M |
| Added | Intercept Pharmaceuticals, Inc. | +121,257 | +21.1% | +$13.6M |
| Added | Sangamo Therapeutics, Inc | +1,300,000 | +96.3% | +$12.4M |
| Added | Kezar Life Sciences, Inc. | +402,071 | +49.1% | +$7.1M |
| Added | Agios Pharmaceuticals, Inc. | +100,000 | +3.5% | +$6.7M |
| Added | Alnylam Pharmaceuticals, Inc. | +59,700 | +3.8% | +$5.6M |
| Added | Esperion Therapeutics, Inc. | +130,000 | +3.8% | +$5.2M |
6 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q4 2018
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | Ionis Pharmaceuticals Inc. | -1,016,334 | -11.6% | $-82.5M |
| Sold out | Regeneron Pharmaceuticals Inc. | -68,156 | -100.0% | $-25.5M |
| Reduced | Incyte Corp. | -188,322 | -4.9% | $-16.2M |
| Reduced | Vertex Pharmaceuticals Inc | -70,445 | -5.1% | $-13.0M |
| Reduced | Gilead Sciences Inc. | -190,000 | -14.3% | $-12.4M |
| Reduced | Celgene Corp | -103,875 | -4.5% | $-9.8M |
| Reduced | Akcea Therapeutics, Inc. | -8,833 | -0.4% | $-250.2K |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q1 2019
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Ionis Pharmaceuticals Inc.COM | 7,725,000 | $627.0M | 15.76% |
| 2 | Incyte Corp.COM | 3,620,000 | $311.4M | 7.83% |
| 3 | Neurocrine Biosciences Inc.COM | 3,366,786 | $296.6M | 7.46% |
| 4 | Vertex Pharmaceuticals IncCOM | 1,300,000 | $239.1M | 6.01% |
| 5 | Sage Therapeutics, Inc.COM | 1,375,229 | $218.7M | 5.50% |
| 6 | Celgene CorpCOM | 2,200,000 | $207.5M | 5.22% |
| 7 | Agios Pharmaceuticals, Inc.COM | 2,978,134 | $200.8M | 5.05% |
| 8 | Alexion Pharmaceuticals, Inc.COM | 1,314,428 | $177.7M | 4.47% |
| 9 | Alnylam Pharmaceuticals, Inc.COM | 1,631,089 | $152.4M | 3.83% |
| 10 | Esperion Therapeutics, Inc.COM | 3,522,964 | $141.4M | 3.56% |
25 more rows. Subscribe for $29/month to see every row, download the data and use the API.